Xconomy’s Digital Events →
Exelixis (NASDAQ: EXEL) is a South San Francisco biotechnology company developing drugs for thyroid cancer, prostate cancer, and other conditions.
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
CMC in Drug Development and Life Cycle Management
© 2007-2022, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.